logo-loader

Small-Cap Snapshot: Bridgline roars on software renewal; Catalyst Pharmaceuticals's rival drug gets FDA approval

Last updated: 13:05 07 May 2019 EDT, First published: 12:02 07 May 2019 EDT

Man pointing at stock arrow

Leaders

Bridgeline Digital Inc (NASDAQ:BLIN), a cloud-based software developer, said a global biopharmaceutical company will continue using its OrchestraCMS platform for three years at a price of $700,000.

Shares surged more than 26% to $7.80.

DRDGOLD Ltd (NYSE:DRD), the South African miner, revealed that it lifted gold production in the most recent quarter, boosted by output from its Far West Gold Recoveries project.

The stock climbed 3.8% to $1.92.

Nano One Materials (CVE:NNO) (OTCMKTS:NNOMF), which develops processing technology for lithium ion battery materials, told investors Tuesday that its technology had been awarded a sixth patent in the US, bringing the total to 13 around the world.

Shares grew 2.3% to C$1.33 in Toronto and 1.7% to US$0.99 on OTC markets.

Ducommun Inc (NYSE:DCO), an aerospace industry supplier, reported first-quarter earnings of $7.5 million on Monday. The Santa Ana, California-based company said it had profit of $0.64 per share, which beat Wall Street expectations of $0.49 per share.

The stock shot up 13% to $48.14.

READ: Buds & Duds: Cannabis stocks trip but Aleafia bucks the trend as it enters German medical cannabis market

Laggards

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) stock collapsed after the Food and Drug Administration approved a competitor's drug late Monday. The company had developed a treatment for the rare autoimmune disease Lambert-Eaton myasthenic syndrome, or LEMS.

Shares plunged more than 39% to $3.70.

Athenex Inc (NASDAQ:ATNX) raised $100 million in a private placement with three institutional investors to help fund the clinical development of its leading pipeline drug to treat cancer.

The stock slipped 2.3% to $12.69.

Intersect ENT Inc (NASDAQ:XENT), the maker of implants used to treat ear, nose and throat conditions, posted a wider-than-expected first-quarter loss, lowered its 2019 guidance and said CEO Lisa Earnhardt will step down on June 5.

Investors were feeling sick, dropping the share price more than 22% to $25.64.

Shares of Nautilus Inc (NYSE:NLS), the exercise equipment maker, reported a wider-than-expected first-quarter loss and sales that fell more than forecast, amid continued weakness in the direct sales segment.

Shares weakened nearly 18% to $4.35.

Video game publisher Glu Mobile Inc (NASDAQ:GLUU) beat Wall Street's bookings target for the first quarter late Monday and posted a slight profit for the period. But the earnings report disappointed with its second-quarter guidance.

The stock powered down more than 15% to $9.47.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour ago